Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
NY-ESO Phase I Study for Prostate Cancer

infection and foreign matter) to fight an illness such as infections or cancer. This vaccine is called NY-ESO-1 protein. NY-ESO protein (an antigen, which is a compound that is recognized by the

  • 142 views
  • 07 Nov, 2020
  • 1 location
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

measurable disease
cyclophosphamide
solid neoplasm
primary cancer
bone marrow procedure
  • 4 views
  • 26 Mar, 2022
  • 35 locations
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

ROS1
immunostimulants
targeted therapy
lymphoma
sarcoma
  • 0 views
  • 07 Oct, 2022
  • 19 locations
Validation and Optimization of Multidimensional Modelling for Never Smoking Lung Cancer Risk Prediction by Multicenter Prospective Study

Lung Cancer is the leading cause of cancer-related deaths in Taiwan and worldwide and the incidence is also increasing. The payment for lung cancer which occupies the largest part of National Health Insurance expense is over 15 billion in 2018. Because about 80% lung cancer patients are smokers in western …

Accepts healthy volunteers
  • 0 views
  • 27 Oct, 2022
  • 1 location
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic

progressive disease
cancer
ny-eso-1
stereotactic radiosurgery
cyclophosphamide
  • 0 views
  • 05 Apr, 2022
  • 1 location
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

This clinical trial is looking at two new vaccines called ChAdOx1-MAGEA3-NYESO and MVA-MAGEA3 given with patients' standard of care treatment (chemotherapy and an immune checkpoint inhibitor).

anticoagulants
measurable disease
cancer chemotherapy
neutrophil count
pembrolizumab
  • 0 views
  • 26 Dec, 2021
  • 8 locations
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

The purpose of this study is to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and in combination …

measurable disease
ny-eso-1
combination therapy
pembrolizumab
intraperitoneal chemotherapy
  • 0 views
  • 07 Oct, 2022
  • 6 locations
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem

measurable disease
ny-eso-1
cancer chemotherapy
neutrophil count
filgrastim
  • 9 views
  • 25 Mar, 2022
  • 1 location
Dose Escalation Study of Immunomodulatory Nanoparticles (PRECIOUS-01)

-1 (NY-ESO-1) cancer-testis antigen peptides encapsulated in a poly(lactic-co-glycolic acid) (PLGA) nanoparticle. PRECIOUS-01 is being developed for the treatment of patients with NY-ESO-1

  • 0 views
  • 25 Mar, 2022
  • 1 location
  • 0 views
  • 18 Oct, 2022
  • 1 location